Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date19 Apr 1949 |
|
MechanismM2 receptor antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc.CA |
First Approval Date01 Jan 1951 |
100 Clinical Results associated with Davis & Geck, Inc.
0 Patents (Medical) associated with Davis & Geck, Inc.
100 Deals associated with Davis & Geck, Inc.
100 Translational Medicine associated with Davis & Geck, Inc.